AI-Powered Biomarkers and Precision Medicine in High-Risk NMIBC

7 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Amanda Nizam, MD, of Cleveland Clinic, speaks with Vignesh Packiam, MD, of Rutgers Cancer Institute, about his innovative study on an AI-powered model designed to predict patient response to intravesical BCG in high-risk non-muscle invasive bladder cancer. They discuss the study's rationale, findings, and implications for precision medicine, highlighting how AI evaluates histopathologic features to guide treatment decisions. Dr. Packiam explores the potential for broader validation through prospective trials like BRIDGE, the challenges of implementing AI in clinical practice, and future applications in tailoring bladder cancer treatment.

#bladdercancer #urology #cancerresearch #cancer
Category
Urology
Be the first to comment

Up Next